{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:48:05Z","timestamp":1791568085146,"version":"4.3.4"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ejim.2015.11.017","type":"journal-article","created":{"date-parts":[[2015,12,12]],"date-time":"2015-12-12T01:37:35Z","timestamp":1449884255000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Adverse drug reactions and organ damage: The skin"],"prefix":"10.1016","volume":"28","author":[{"given":"Angelo V.","family":"Marzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2015.11.017_bb0005","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2015.11.017_bb0010","first-page":"765","article-title":"Rates of cutaneous reactions to drugs","volume":"137","author":"Bigby","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.iac.2004.03.007","article-title":"Dermatologic drug reactions","volume":"24","author":"McKenna","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.ejim.2015.11.017_bb0020","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2165\/00002018-200730110-00003","article-title":"Drug-induced skin, nail and hair disorders","volume":"30","author":"Valeyrie-Allanore","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.ejim.2015.11.017_bb0025","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00029330-200804020-00019","article-title":"Severe cutaneous adverse drug reactions: a review on epidemiology, etiology, clinical manifestation and pathogenesis","volume":"121","author":"Martin","year":"2008","journal-title":"Chin Med J"},{"key":"10.1016\/j.ejim.2015.11.017_bb0030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/ACI.0b013e32833b1eb3","article-title":"Genetic and ethnic risk factors associated with drug hypersensitivity","volume":"10","author":"Kim","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0035","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaci.2015.06.022","article-title":"New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity","volume":"136","author":"Pirmohamed","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.ejim.2015.11.017_bb0045","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1398-9995.1997.tb01017.x","article-title":"Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey","volume":"52","author":"Hunziker","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.ejim.2015.11.017_bb0050","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.tox.2004.12.023","article-title":"Drug-induced exanthems","volume":"209","author":"Yawalkar","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.ejim.2015.11.017_bb0055","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1365-2222.2000.00847.x","article-title":"Infiltration of cytotoxic T-cells in druginduced eruptions","volume":"30","author":"Yawalkar","year":"2000","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.ejim.2015.11.017_bb0060","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1067\/mai.2000.110922","article-title":"Evidence for a role for IL-5 and eotaxin in activating and recruitring eosinophils in drug-induced cutaneous eruptions","volume":"106","author":"Yawalkar","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0031-6997(24)01501-1","article-title":"Cutaneous drug reactions","volume":"53","author":"Svensson","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ejim.2015.11.017_bb0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335621","article-title":"Drug-induced angioedema","volume":"97","author":"Lerch","year":"2012","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.ejim.2015.11.017_bb0075","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00128071-200304060-00005","article-title":"Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions","volume":"4","author":"Crowson","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00128071-200102030-00004","article-title":"Drug-induced urticaria","volume":"2","author":"Shipley","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0085","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1468-3083.2006.01744.x","article-title":"The inflammatory response in drug-induced acute urticaria: ultrastructural study of the dermal microvascular unit","volume":"20","author":"Criado","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0090","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2332\/allergolint.12-RAI-0493","article-title":"Recent advances in drug-induced angioedema","volume":"61","author":"Inomata","year":"2012","journal-title":"Allergol Int"},{"key":"10.1016\/j.ejim.2015.11.017_bb0095","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2015.06.021","article-title":"Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema","volume":"136","author":"Kowalski","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0162-3109(99)00107-1","article-title":"Angioedema due to angiotensin-converting enzyme inhibitors","volume":"44","author":"Agostoni","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.ejim.2015.11.017_bb0105","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/S0140-6736(02)08914-6","article-title":"Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors","volume":"359","author":"Adam","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2015.11.017_bb0110","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJMoa1312524","article-title":"A randomized trial of icatibant in ACE-inhibitor-induced angioedema","volume":"372","author":"Ba\u015f","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2015.11.017_bb0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-5945-5-5","article-title":"Erythroderma: a clinical study of 97 cases","volume":"5","author":"Akhyani","year":"2005","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0120","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1468-3083.2009.03526.x","article-title":"Acquired erythroderma in adults: a clinical and prognostic study","volume":"24","author":"Khaled","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0125","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-4632.2004.02100.x","article-title":"Erythroderma in adults: a report of 80 cases","volume":"44","author":"Rym","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0130","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1001\/archderm.1994.01690120039004","article-title":"Erythroderma\u2014a clinical pathological study of 56 cases","volume":"130","author":"Botella-Estradas","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0135","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1034\/j.1600-0560.2000.027009436.x","article-title":"Expression of VCAM-1, ICAM-1, E-selectin, and P-selectin on endothelium in situ in patients with erythroderma, mycosis fungoides and atopic dermatitis","volume":"27","author":"Sigurdsson","year":"2000","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0140","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.clindermatol.2004.06.018","article-title":"Life-threatening erythroderma: diagnosing and treating the \u201cred man\u201d","volume":"23","author":"Rothe","year":"2005","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0145","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens\u2013Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0150","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Severe cutaneous adverse reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens\u2013Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0155","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"A clinical classification of cases of toxic epidermal necrolysis, Stevens\u2013Johnson syndrome and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0160","doi-asserted-by":"crossref","first-page":"187.e1","DOI":"10.1016\/j.jaad.2013.05.002","article-title":"Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity of illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0170","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1398-9995.2006.01295.x","article-title":"Ocular manifestations and complications of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: an Asian series","volume":"62","author":"Yip","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.ejim.2015.11.017_bb0175","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.1996.tb03598.x","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"135","author":"Rzany","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0180","first-page":"625","article-title":"Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy","volume":"13","author":"Paulmann","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ejim.2015.11.017_bb0185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.12788\/j.sder.0058","article-title":"Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management","volume":"33","author":"Mockenhaupt","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.ejim.2015.11.017_bb0195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.12788\/j.sder.0059","article-title":"Severe cutaneous adverse reactions: impact of immunology, genetics, and pharmacology","volume":"33","author":"Harp","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.ejim.2015.11.017_bb0200","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/039463200702000313","article-title":"Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"20","author":"Marzano","year":"2007","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0205","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.4049\/jimmunol.171.5.2556","article-title":"Intracellular mediators of granulysin-induced cell death","volume":"171","author":"Okada","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0210","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.ejim.2015.11.017_bb0215","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/jid.2012.330","article-title":"TNF-\u03b1 and IFN-\u03b3 are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis","volume":"133","author":"Viard-Leveugle I1","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0220","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2133\/dmpk.DMPK-11-RV-116","article-title":"A recent update of pharmacogenomics in drug-induced severe skin reactions","volume":"27","author":"Wei","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.ejim.2015.11.017_bb0225","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.ejim.2015.11.017_bb0235","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens\u2013Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejim.2015.11.017_bb0240","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0245","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/2042098611404094","article-title":"Systematic review of treatments for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality","volume":"2","author":"Roujeau","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.ejim.2015.11.017_bb0250","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0255","first-page":"37","article-title":"Pustuloses exanth\u00e9matiques aigu\u00ebs g\u00e9n\u00e9ralis\u00e9es, \u00e0 propos de 4 cas","volume":"107","author":"Beylot","year":"1980","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0260","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP)\u2014a clinical reaction pattern","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0265","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)\u2014results of a multinational case\u2013control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0270","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2340\/00015555-0438","article-title":"Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia","volume":"88","author":"Chang","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0275","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1440-0960.2011.00845.x","article-title":"Acute generalised exanthematous pustulosis","volume":"53","author":"Fernando","year":"2012","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0280","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/ndt\/17.10.1857","article-title":"Acute reversible renal failure in acute generalized exanthematous pustulosis","volume":"17","author":"Brandenburg","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2015.11.017_bb0285","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/bjd.13152","article-title":"Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature","volume":"171","author":"van Hattem","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0290","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1600-0560.2010.01612.x","article-title":"The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis","volume":"37","author":"Kardaun","year":"2010","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0295","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/archderm.1991.01680080069004","article-title":"Acute generalized exanthematous pustulosis. Analysis of 63 cases","volume":"127","author":"Roujeau","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0300","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2133.2008.08638.x","article-title":"Acute generalized exanthematous pustulosis does not always have a drug-related cause","volume":"159","author":"Birnie","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0305","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/S0002-9440(10)64486-0","article-title":"Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation","volume":"161","author":"Schmid","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0310","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nri3024","article-title":"Neutrophils in the activation and regulation of innate and adaptive immunity","volume":"11","author":"Mantovani","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0315","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1468-3083.2010.03771.x","article-title":"Increased circulating. frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis","volume":"25","author":"Kabashima","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0325","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1172\/JCI12118","article-title":"T-cell involvement in drug-induced acute generalized exanthematous pustulosis","volume":"107","author":"Britschgi","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejim.2015.11.017_bb0330","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/bjd.12502","article-title":"Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients","volume":"169","author":"Hotz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0335","doi-asserted-by":"crossref","first-page":"693.e1","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: Part I. Clinical perspectives","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0340","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0345","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2015.11.017_bb0350","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0355","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1365-2133.2007.07807.x","article-title":"The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations","volume":"156","author":"Shiohara","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0360","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1365-2133.2003.05584.x","article-title":"A 6-month prospective survey of cutaneous drug reactions in a hospital setting","volume":"149","author":"Fiszenson-Albala","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0365","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.mcna.2010.03.004","article-title":"Visceral involvements and long-term sequelae in drug-induced hypersensitivity syndrome","volume":"94","author":"Kano","year":"2010","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.ejim.2015.11.017_bb0370","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4168\/aair.2010.2.2.123","article-title":"Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and Stevens\u2013Johnson syndrome","volume":"2","author":"Jeung","year":"2010","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.ejim.2015.11.017_bb0375","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.ejim.2015.11.017_bb0380","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1468-3083.2008.02585.x","article-title":"Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan","volume":"22","author":"Chiou","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0385","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2230.2010.03967.x","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking","volume":"36","author":"Walsh","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0390","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jbspin.2013.05.002","article-title":"DRESS syndrome","volume":"81","author":"Descamps","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ejim.2015.11.017_bb0395","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-105-2-179","article-title":"Differences in metabolism of sulphonamides predisposing to idiosyncratic toxicity","volume":"105","author":"Shear","year":"1986","journal-title":"Ann Intern Med"},{"issue":"1 suppl","key":"10.1016\/j.ejim.2015.11.017_bb0400","doi-asserted-by":"crossref","first-page":"95S","DOI":"10.1038\/jid.1995.19","article-title":"Lymphocyte activation in cutaneous drug reactions","volume":"105","author":"Hertl","year":"1995","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0405","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0536.2009.01659.x","article-title":"Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS)","volume":"62","author":"Santiago","year":"2010","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ejim.2015.11.017_bb0410","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1046\/j.1365-2133.1998.02559.x","article-title":"Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome","volume":"139","author":"Choquet-Kastylevsky","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0415","first-page":"301","article-title":"Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms","volume":"137","author":"Descamps","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0420","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2133.2003.05368.x","article-title":"Carbemazepine-induced hypogammaglobulinaemia and reactivation of human herpesvirus 6 infection demonstrated by real-time quantitative polymerase chain reaction","volume":"149","author":"Aihara","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0425","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.4049\/jimmunol.0804002","article-title":"Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome","volume":"182","author":"Takahashi","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0430","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5415\/apallergy.2015.5.2.59","article-title":"Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms","volume":"5","author":"Dao","year":"2015","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.ejim.2015.11.017_bb0435","doi-asserted-by":"crossref","first-page":"709.e1","DOI":"10.1016\/j.jaad.2013.01.032","article-title":"DRESS syndrome: Part II. Management and therapeutics","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0440","doi-asserted-by":"crossref","first-page":"CS57","DOI":"10.12659\/MSM.883198","article-title":"Treatment of DIHS\/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir\u2014a hypothesis","volume":"18","author":"Moling","year":"2012","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ejim.2015.11.017_bb0445","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.autrev.2012.08.005","article-title":"Skin involvement in cutaneous and systemic vasculitis","volume":"12","author":"Marzano","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejim.2015.11.017_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2015.11.017_bb0455","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1345\/aph.1A124","article-title":"Cutaneous and systemic manifestations of drug-induced vasculitis","volume":"36","author":"ten Holder","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ejim.2015.11.017_bb0460","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0190-9622(98)70039-8","article-title":"Cutaneous small-vessel vasculitis","volume":"39","author":"Lotti","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0465","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00128071-200809020-00001","article-title":"Clinical approach to cutaneous vasculitis","volume":"9","author":"Chen","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0470","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2559.2009.03443.x","article-title":"The histological assessment of cutaneous vasculitis","volume":"56","author":"Carlson","year":"2010","journal-title":"Histopathology"},{"key":"10.1016\/j.ejim.2015.11.017_bb0475","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/archderm.142.2.155","article-title":"Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis","volume":"142","author":"Bahrami","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejim.2015.11.017_bb0480","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.autrev.2012.08.003","article-title":"The kaleidoscopic manifestations of systemic vasculitis","volume":"12","author":"Sinico","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejim.2015.11.017_bb0485","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.autrev.2011.04.004","article-title":"Dysregulated neutrophil\u2013endothelial interaction in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides: implications for pathogenesis and disease intervention","volume":"10","author":"Hu","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejim.2015.11.017_bb0490","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0738-081X(99)00066-8","article-title":"Gamma\/delta T lymphocytes and infection: pathogenesis of leukocytoclastic cutaneous necrotizing vasculitis","volume":"17","author":"Comacchi","year":"1999","journal-title":"Clin Dermatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620515004148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620515004148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T15:21:15Z","timestamp":1748704875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620515004148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":96,"alternative-id":["S0953620515004148"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2015.11.017","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse drug reactions and organ damage: The skin","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2015.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}